Innovation Showcases
Allogeneic stem cell-based immunotherapy manufacturing requires reliable large-scale protocols to produce high-quality immune cells totaling up to 1.5 x 10^9 cells per dose. The high cost of optimization and manufacturing challenges often hampers the development of such protocols In this talk, we present a robust suspension culture protocol for scalable differentiation of human pluripotent stem cells (hPSCs) to CD34+ hematopoietic stem and progenitor cells (HSPCs). With high-volume culture in mind, the seed, feed, and harvest steps were optimized in 2 mL cultures and then scaled up to 100 mL, where multipotent HSPCs were generated at more than 1.0 x 10^6 CD34+ cells per 1 mL culture volume. HSPCs were then differentiated to T, NK, and B cells using specialized differentiation culture systems. This protocol provides a path to scalable manufacturing of high-quality hPSC-derived immune cells.